Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mi-Gel for entry dyspareunia
ACTRN12619001163190Phase 3Completed
- Sponsor
- Women's Health & Research Institute of Australia
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyspareunia comparing Mi-Gel with Placebo (2 arms). Primary endpoint: Change in pain of vaginal penetration. Started Nov 2019; status: completed.
02
Drugs
amitriptyline + estriol
03
Conditions
dyspareunia
Beyond the preview
Go deeper on ACTRN12619001163190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001163190.